Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Otezla

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

    The drug is the first IL-23 inhibitor approved for children from the age of six

    - PMLiVE

    Amgen commits $650m to US manufacturing expansion

    The investment is expected to generate up to 750 new jobs

    - PMLiVE

    Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

    The phase 3 study included around 2,600 patients

    - PMLiVE

    Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies

    The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population

    - PMLiVE

    Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

    Approximately 125 million people globally are living with some form of psoriasis

    - PMLiVE

    Novartis and Matchpoint enter inflammatory disease partnership worth $1bn

    The companies will focus on inflammatory diseases that have been historically difficult to treat

    - PMLiVE

    Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

    Almost one million new cases of gastric cancer are diagnosed globally every year

    - PMLiVE

    FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis

    The Stelara biosimilar now offers all dosage forms and strengths of its reference product

    - PMLiVE

    UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

    Approximately 125 million people worldwide are affected by some form of psoriasis

    - PMLiVE

    Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis

    The inflammatory condition affects approximately 30% of psoriasis patients

    - PMLiVE

    Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

    Immunoglobulin G4-related disease affects approximately 20,000 people in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links